Silo Pharma rises on positive data for its Alzheimer's disease therapy

Silo Pharma

24/01/2024 18:16

** Shares of drug developer Silo Pharma  SILO.O  rise 1.8%
to $1.42
    ** Co announces positive results from pre-clinical study
testing its experimental Alzheimer's disease therapy, SPC-14, in
mice
    ** Says mice were treated twice daily with the therapy in a
study conducted at Columbia University
    ** Data showed therapy was effective against high levels of
luteinizing hormone, which plays a role in age-related cognitive
decline - SILO
    ** Therapy helped in reducing learned helplessness and
anxiety symptoms in mice - SILO
    ** Stock fell 45.3% in the last 12 months

 (Reporting by Sneha S K)
 ((Sneha.SK@thomsonreuters.com;))